206 related articles for article (PubMed ID: 35672926)
1. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
Arnold DL; Sprenger T; Bar-Or A; Wolinsky JS; Kappos L; Kolind S; Bonati U; Magon S; van Beek J; Koendgen H; Bortolami O; Bernasconi C; Gaetano L; Traboulsee A
Mult Scler; 2022 Oct; 28(12):1927-1936. PubMed ID: 35672926
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
3. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
[TBL] [Abstract][Full Text] [Related]
4. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Turner B; Cree BAC; Kappos L; Montalban X; Papeix C; Wolinsky JS; Buffels R; Fiore D; Garren H; Han J; Hauser SL
J Neurol; 2019 May; 266(5):1182-1193. PubMed ID: 30820738
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
6. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
[TBL] [Abstract][Full Text] [Related]
7. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.
Kolind S; Gaetano L; Assemlal HE; Bernasconi C; Bonati U; Elliott C; Hagenbuch N; Magon S; Arnold DL; Traboulsee A
Mult Scler; 2023 May; 29(6):741-747. PubMed ID: 37148240
[TBL] [Abstract][Full Text] [Related]
9. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
10. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
11. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab: A Review in Multiple Sclerosis.
Syed YY
CNS Drugs; 2018 Sep; 32(9):883-890. PubMed ID: 30171504
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY).
Chisari CG; Bianco A; Brescia Morra V; Calabrese M; Capone F; Cavalla P; Chiavazza C; Comi C; Danni M; Filippi M; Iaffaldano P; Lanzillo R; Lo Fermo S; Lucisano A; Lugaresi A; Lus G; Marfia GA; Marinelli F; Mirabella M; Moiola L; Perin C; Realmuto S; Toscano S; Trojano M; Vecchio D; Patti F;
Neurotherapeutics; 2023 Oct; 20(6):1696-1706. PubMed ID: 37610702
[TBL] [Abstract][Full Text] [Related]
15. Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.
Kolind S; Abel S; Taylor C; Tam R; Laule C; Li DKB; Garren H; Gaetano L; Bernasconi C; Clayton D; Vavasour I; Traboulsee A
Neuroimage Clin; 2022; 35():103109. PubMed ID: 35878575
[TBL] [Abstract][Full Text] [Related]
16. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
[TBL] [Abstract][Full Text] [Related]
18. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO.
Gibiansky E; Petry C; Mercier F; Günther A; Herman A; Kappos L; Hauser S; Yamamoto Y; Wang Q; Model F; Kletzl H
Br J Clin Pharmacol; 2021 Jun; 87(6):2511-2520. PubMed ID: 33202059
[TBL] [Abstract][Full Text] [Related]
19. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials.
Krishnan AP; Song Z; Clayton D; Gaetano L; Jia X; de Crespigny A; Bengtsson T; Carano RAD
Radiology; 2022 Mar; 302(3):662-673. PubMed ID: 34904871
[TBL] [Abstract][Full Text] [Related]
20. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]